Trials / Completed
CompletedNCT04795674
Target ADHD Executive Working Memory Study
Behavioral and Neural Target Engagement for ADHD Executive Working Memory Training
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Hartford Hospital · Academic / Other
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess whether or not a novel executive working memory training intervention for Attention-Deficit/Hyperactivity Disorder can engage frontoparietal brain network treatment targets and behavioral performance.
Detailed description
This proposal seeks support for a 2-year milestone-driven R61 initial test of target engagement in n=62 ADHD diagnosed adolescents randomized to a 'sham training' placebo or to train 4 times each week using 4 different EWM exercises that have been combined into the format of a typical cognitive training intervention. Exercise difficulty levels in the active intervention will increase across 5 weeks to continually challenge EWM ability. EWM training will use a novel, remotely-supervised 'at home' computerized training approach. If R61 EWM training target engagement milestones are met, a 3-year R33 phase will begin. The R33 will replicate target engagement in another randomized placebo-controlled trial of n=90 new ADHD adolescents and attempt to establish a convincing link between the hypothesized targets and ADHD symptom expression. It also will characterize ADHD brain activity or EWM ability changes relative to typical levels seen in an n=40 non-ADHD control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | EWM Training | Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance. |
| BEHAVIORAL | Placebo Training | Computerized tasks with comparable engagement that do not tap executive working memory processes |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2023-03-19
- Completion
- 2023-03-19
- First posted
- 2021-03-12
- Last updated
- 2023-08-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04795674. Inclusion in this directory is not an endorsement.